Infallible Pharma Private Limited - Due diligence report

A 360° intelligence report on Infallible Pharma: trust score, financial health, credit view, compliance, directors, growth and distress sign…

2019-03-20 Mumbai, Maharashtra Active Unlisted
Share
IP Infallible Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Infallible Pharma — 360° Intelligence Report

Generated from MCA filings & public records
81/100
Trust Score
Low Risk

Infallible Pharma is assessed as Low Risk with a Trust Score of 81/100. Infallible Pharma is an active private limited indian non-government company incorporated in 2019, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Infallible Pharma Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
81/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.
  • Externally credit-rated (BB-).

Charges position: 3 open (36.95 cr) · 1 satisfied (8.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others4 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
SHREEKANT KRISHNA SHETTY 01234567 Director 01/04/2018 6 yrs Approved
HARI OM 01234567 Director 01/04/2018 6 yrs Approved
Hari Krishnababu Naidu 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 3 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: SHREEKANT KRISHNA SHETTY (Whole-time director) · HARI OM (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 60 · Distress 65
Growth signals & trust indicators
Asset base grew 2.1x - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 7 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Outside liabilities up 24% in a year.
3 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence84/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment61/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 36.95 cr already registered.
  • Compliance record supports lending.
Investor view65/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
Hari Krishnababu Naidu
31 Mar 2025
Latest balance sheet
Filed with ROC
16 Dec 2024
Director appointed
Hari Krishnababu Naidu (Director)
21 Aug 2024
Charge created
Others - 8.00 cr
24 Nov 2023
Charge created
Others - 7.50 cr
07 Sep 2023
Charge satisfied
Others
27 Oct 2022
Charge created
Others - 8.00 cr
07 Jul 2022
Director ceased
DEVIDAS BALKRISHNA BHATLAWANDE
11 Nov 2021
Securities allotted
222222 Equity Shares - 22.22 Lakh raised
26 Aug 2021
Charge created
Others - 21.45 cr
01 May 2021
Securities allotted
1987500 Equity Shares - 1.99 cr raised
31 Mar 2021
Share transfer (FY 2021)
3500.00000000 shares to HARI OM
23 Mar 2021
Director ceased
HARI OM
22 Mar 2021
Securities allotted
1987500 Equity Shares - 1.99 cr raised
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BB- from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Sundyotanumandis U24230GJ2011PTC067414 Ahmedabad, Gujarat, India
Gorakh Nath Formulations U24233UP2011PTC043224 Meerut, Uttar Pradesh, India
Panchwati Prayogshala Private Limited U74899UR1982PTC032733 Roorkee, Uttarakhand, India
Nayakem Organics Private Limited U24100MH1990PTC055886 Mumbai, Maharashtra, India
Leeds Life Sciences Private Limited U24100DL2007PTC166537 New Delhi, Delhi, India
Organica Aromatics Private Limited U24249KA1999PTC025623 Bangalore, Karnataka, India
Samrat Sea Brines Private Limited U24298GJ2011PTC067310 Patan, Gujarat, India
G D Dyestuff Industries Limited U24114DL1987PLC029984 New Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Infallible Pharma before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Infallible Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 60/100, margin trends, ownership structure and peer set for Infallible Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 81/100, distress signals and MSME payment-delay disclosures - know whether Infallible Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Infallible Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Infallible Pharma an active company?

Infallible Pharma has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Infallible Pharma financially healthy?

Infallible Pharma has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with Infallible Pharma?

Its overall Trust Score is 81/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Infallible Pharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Infallible Pharma have loans or charges against its assets?

3 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Infallible Pharma up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Infallible Pharma?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.